You are here: Industry Insights > Takeda

News List

Evotec, Takeda Enter Long-Term Research Alliance contractpharma
April 07, 2020
Evotec will support multiple Takeda programs targeting oncology, rare diseases, neuroscience and gastroenterology.
Evox and Takeda sign deal to collaborate on rare disease treatments europeanpharmaceuticalreview
April 02, 2020
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
Takeda Appoints New Country Head for India expresspharma
April 02, 2020
Koki Sato, a seasoned biopharmaceutical leader with over 17 years of experience across geographies has been assigned as the new lead of Takeda’s business in India.
Takeda, Evox link up to the tune of $882m pharmatimes
March 30, 2020
Evox has announced a new rare disease collaboration with Takeda to develop up to five novel protein replacement and mRNA therapies.
Codexis Signs Strategic Collaboration, License Agreement with Takeda americanpharmaceuticalreview
March 27, 2020
Codexis has announced the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of novel gene therapies ...
Takeda partners with Codexis on gene therapies for rare diseases pharmaceutical-technology
March 25, 2020
Takeda Pharmaceutical has signed a strategic collaboration and licence agreement with biotherapeutics developer Codexis to research and create gene therapies for rare disorders.
Codexis, Takeda Sign Gene Therapy Collaboration contractpharma
March 25, 2020
Partnership to leverage Codexis’ protein engineering platform to advance novel gene therapies for rare genetic disorders。
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial americanpharmaceuticalreview
March 11, 2020
Takeda Pharmaceutical announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.
Development initiated for a plasma-derived COVID-19 therapy europeanpharmaceuticalreview
March 10, 2020
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed to treat infected, high-risk individuals with COVID-19.
Takeda completes sale of select OTC and non-core assets to Acino pharmaceutical-business-review
March 04, 2020
Takeda Pharmaceutical announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East Middle East ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page